March 2024 Newsletter
Welcome to the March Cresset newsletter where we share our latest results for GPCR benchmarks using Flare™ FEP, Cresset wins ...
News
Date: June 1st
Venue: Novartis, Cambridge, MA
Presenting companies: Boehringer Ingelheim, Broad Institute, Novartis, Cresset
Last chance to register
Scientific program: June 16th
Workshops: June 17th
Venue: Granta Centre, Cambridgeshire, UK Presenting companies: Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Monsanto, Novartis, Takeda, University of Hertfordshire, Cresset
Last chance to register
Cresset’s Spark software for bioisosteric replacement now includes reagent databases based on eMolecules building blocks. This case study describes how Spark was used to identify alternative R-groups for selective inhibitors of the c-Met Kinase. Using the eMolecules reagent databases ensured that results were tethered to molecules that are readily synthetically accessible.
Many customers engage Cresset Discovery Services to find a chemical starting point for their project. The input could be a competitor compound, a peptide, or a compound that is unsuitable for development for toxicity or patent reasons. Martin Slater explains how Cresset computational methods are an extremely cost effective way of identifying promising candidate compounds.
In drug discovery, data is king. Gathering the right information makes it easier to design better compounds, faster. How can you be sure that you are getting the most out of your SAR data? And how easy is it to see where the gaps are in your data? Read Giovanna Tedesco and Katriona Scoffin’s article Where are the gaps in your data? published in International Pharmaceutical Industry.